GFH375 targets both GTP-bound and GDP-bound states of KRAS G12D proteins, the most prevalent RAS mutation in solid tumors, in patients with advanced colorectal cancer, pancreatic cancer, and non-small cell lung cancer. (Nat Med)
Oral KRAS G12D inhibitor GFH375 evaluated in phase 1 trial
The CRC Digest